Medicure (MCUJF) Downgraded by ValuEngine

Medicure (OTCMKTS:MCUJF) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Monday.

Shares of MCUJF stock traded up $0.07 during trading on Monday, reaching $5.25. The company’s stock had a trading volume of 1,100 shares, compared to its average volume of 1,976. The company has a debt-to-equity ratio of 2.38, a quick ratio of 2.79 and a current ratio of 2.83. The stock has a market capitalization of $82.25, a P/E ratio of 5.63 and a beta of 0.84. Medicure has a 1-year low of $4.64 and a 1-year high of $7.46.

How to Become a New Pot Stock Millionaire

COPYRIGHT VIOLATION NOTICE: “Medicure (MCUJF) Downgraded by ValuEngine” was first reported by WKRB News and is the property of of WKRB News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.wkrb13.com/2018/04/03/medicure-mcujf-downgraded-by-valuengine.html.

About Medicure

Medicure Inc, a specialty pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, Barbados, and India. The company primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply